Their study demonstrated that Luteolin could suppress the EGF-induced activities of EGFR signaling in human breast cancer cell lines and suggested that STAT3, MAPK/ERK1/2, and PI3K/Akt signaling pathways are the main pathways through which Luteolin exhibits its effects on EGFR signaling [118]. This evidence concerns the gene MAPK3 and breast carcinoma.